Hugh Watson Selected Research

satavaptan

7/2022	Spontaneous bacterial peritonitis has no effect on the long-term prognosis of cirrhosis patients with ascites.
1/2022	Risk Factors for Hepatic Hydrothorax in Cirrhosis Patients with Ascites - A Clinical Cohort Study.
11/2019	Improvement of hyponatremia in cirrhosis is associated with improved complex information processing.
5/2019	Serum sodium as a risk factor for hepatic encephalopathy in patients with cirrhosis and ascites.
1/2019	Quality of life measures predict mortality in patients with cirrhosis and severe ascites.
1/2019	Effect of proton pump inhibitors on the risk and prognosis of infections in patients with cirrhosis and ascites.
10/2018	Un-precipitated acute kidney injury is uncommon among stable patients with cirrhosis and ascites.
10/2016	Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites.
7/2016	Epilepsy as a risk factor for hepatic encephalopathy in patients with cirrhosis: a cohort study.
1/2016	Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hugh Watson Research Topics

Disease

22	Ascites 07/2022 - 12/2006
21	Fibrosis (Cirrhosis) 07/2022 - 12/2006
8	Hepatic Encephalopathy 01/2022 - 12/2006
3	Infections 01/2022 - 01/2019
3	Hyponatremia 11/2019 - 07/2008
3	Peritonitis 01/2019 - 12/2006
3	Hemorrhage 01/2019 - 12/2006
2	Liver Cirrhosis (Hepatic Cirrhosis) 04/2022 - 08/2010
2	Body Weight (Weight, Body) 11/2021 - 07/2008
2	Pain (Aches) 01/2021 - 05/2020
2	End Stage Liver Disease 01/2019 - 01/2016
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2022
1	Hydrothorax 01/2022
1	Inflammation (Inflammations) 01/2022
1	Arthralgia (Joint Pain) 05/2020
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2019
1	Liver Diseases (Liver Disease) 07/2016
1	Edema (Dropsy) 12/2012
1	Hepatorenal Syndrome 12/2006

Drug/Important Bio-Agent (IBA)

15	satavaptanIBA 07/2022 - 07/2008
11	SodiumIBA 04/2022 - 12/2006
7	DiureticsIBA 01/2022 - 07/2008
4	Proton Pump InhibitorsIBA 01/2022 - 10/2016
4	AlbuminsIBA 01/2022 - 11/2015
4	Vasopressins (Vasopressin)IBA 11/2019 - 07/2008
4	Lactulose (Duphalac)FDA LinkGeneric 10/2019 - 11/2015
3	Spironolactone (Aldactone)FDA LinkGeneric 01/2022 - 08/2010
3	BilirubinIBA 01/2022 - 11/2015
3	BenzodiazepinesIBA 04/2018 - 11/2015
3	Antidiuretic Hormone Receptor AntagonistsIBA 11/2015 - 07/2008
2	Natriuretic PeptidesIBA 04/2022 - 11/2021
2	CreatinineIBA 01/2022 - 11/2015
2	Rifaximin (L 105)FDA Link 01/2022 - 07/2016
2	Furosemide (Lasix)FDA LinkGeneric 01/2022 - 11/2015
2	ametantrone (HAQ)IBA 01/2021 - 05/2020
2	barbituric acid (barbiturate)IBA 07/2016 - 11/2015
2	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 01/2012 - 08/2010
1	Natriuretic AgentsIBA 04/2022
1	Atrial Natriuretic Factor (ANF)IBA 04/2022
1	Antiviral Agents (Antivirals)IBA 01/2022
1	Carnitine (L-Carnitine)FDA LinkGeneric 01/2022
1	Insulin (Novolin)FDA Link 01/2022
1	KynurenineIBA 01/2022
1	LipidsIBA 01/2022
1	Tryptophan (L-Tryptophan)FDA Link 01/2022
1	Simvastatin (Zocor)FDA LinkGeneric 01/2022
1	Hormones (Hormone)IBA 11/2021
1	UlaritideIBA 11/2021
1	Biomarkers (Surrogate Marker)IBA 11/2021
1	Serum AlbuminIBA 01/2019
1	PotassiumIBA 11/2015

Therapy/Procedure

4	Therapeutics 01/2022 - 08/2010
1	Intravenous Administration 04/2022
1	Drug Therapy (Chemotherapy) 11/2021